RDPAC药品推广行为准则 - IFPMA

研
制
开
发
制
药
企
业
协
会
德素养,以保证其能够科学地向医
生和医疗机构介绍药品的安全性、
有效性以及指导医生合理用药;同
时收集药品不良反应信息并及时向
生产企业反馈、提出有效措施及处
置办法;认真了解临床需求,提供
科学的药学服务,以实现患者的最
大利益。
14
RDPAC会员公司有责任处理
并矫正违反准则的行为。RDPAC
接受来自会员公司且符合相关程
序要求的投诉。一旦确定有违反
RDPAC准则的行为发生,RDPAC
应尽快使违反行为得到纠正。
本行为准则于2012年7月1日
起生效,并取代2002年版的FRPIA
药品推广行为准则(第二版)及
2006年版和2010版RDPAC药品推
广行为准则。
medical science and pharmacy, as
well as qualification of professional
ethics so that they are sufficiently
capable of providing healthcare professionals
with newest information on
the use of pharmaceutical products,
especially the safety, efficacy, and
rational use of a drug product; collecting
and reporting back to their
companies all the adverse drug reports
for a solution; understanding the
clinical needs in order to improve the
quality of services and serve the best
interests of patients.
RDPAC member companies are accountable
for addressing and correcting
infringements under the RDPAC
Code. RDPAC is open to receive
complaints from its member companies,
in accordance with its operating
procedures. Where it is determined
that there has been a breach of the
RDPAC Code, the objective is to correct
the matter as rapidly as possible.
Effective July 1, 2012, this Code
replaces the FRPIA Code of Pharmaceutical
Marketing Practices (2nd
Edition, 2002), the RDPAC Code of
Practice on the Promotion of Pharmaceutical
Products (2006) and (2010).